Potential use of melatonin in skin cancer treatment

A review of current biological evidence

Mohammad Hossein Pourhanifeh, Mostafa Mahdavinia, Russel J Reiter, Zatollah Asemi

Research output: Contribution to journalArticle

Abstract

Skin cancer, particularly melanoma, is a leading cause of death worldwide. The therapeutic methods for this malignancy are not effective, and due to the side effects of these treatments, applying an appropriate alternative or complementary treatment is important. According to available data, melatonin as the main product of the pineal gland has oncostatic and antitumoral properties. Also, melatonin acts as an anti-inflammatory and reactive oxygen species inducer agent which suppresses the growth of tumors. It also has apoptosis induction characteristics through regulating signaling pathways, including heat shock protein 70, nuclear factor-erythroid 2 p45-related factor 2 and others. Thus, adding melatonin to chemo- and radiotherapy may have synergistic therapeutic effects and increase the survival time in patients with skin cancer. Few clinical studies have evaluated the efficacy of melatonin in skin cancer. Based on the related mechanisms, this review discusses about how melatonin may improve outcomes in skin cancer patients.

Original languageEnglish (US)
JournalJournal of Cellular Physiology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Oncology
Skin Neoplasms
Melatonin
Skin
Therapeutics
HSP70 Heat-Shock Proteins
Pineal Gland
Chemotherapy
Radiotherapy
Therapeutic Uses
Tumors
Cause of Death
Melanoma
Reactive Oxygen Species
Neoplasms
Anti-Inflammatory Agents
Apoptosis
Drug Therapy
Survival
Growth

Keywords

  • malignancy
  • melanoma
  • Melatonin
  • skin cancer

ASJC Scopus subject areas

  • Physiology
  • Clinical Biochemistry
  • Cell Biology

Cite this

Potential use of melatonin in skin cancer treatment : A review of current biological evidence. / Pourhanifeh, Mohammad Hossein; Mahdavinia, Mostafa; Reiter, Russel J; Asemi, Zatollah.

In: Journal of Cellular Physiology, 01.01.2019.

Research output: Contribution to journalArticle

@article{8bcad14b65c445279ddfa1d0e284e590,
title = "Potential use of melatonin in skin cancer treatment: A review of current biological evidence",
abstract = "Skin cancer, particularly melanoma, is a leading cause of death worldwide. The therapeutic methods for this malignancy are not effective, and due to the side effects of these treatments, applying an appropriate alternative or complementary treatment is important. According to available data, melatonin as the main product of the pineal gland has oncostatic and antitumoral properties. Also, melatonin acts as an anti-inflammatory and reactive oxygen species inducer agent which suppresses the growth of tumors. It also has apoptosis induction characteristics through regulating signaling pathways, including heat shock protein 70, nuclear factor-erythroid 2 p45-related factor 2 and others. Thus, adding melatonin to chemo- and radiotherapy may have synergistic therapeutic effects and increase the survival time in patients with skin cancer. Few clinical studies have evaluated the efficacy of melatonin in skin cancer. Based on the related mechanisms, this review discusses about how melatonin may improve outcomes in skin cancer patients.",
keywords = "malignancy, melanoma, Melatonin, skin cancer",
author = "Pourhanifeh, {Mohammad Hossein} and Mostafa Mahdavinia and Reiter, {Russel J} and Zatollah Asemi",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/jcp.28129",
language = "English (US)",
journal = "Journal of Cellular Physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Potential use of melatonin in skin cancer treatment

T2 - A review of current biological evidence

AU - Pourhanifeh, Mohammad Hossein

AU - Mahdavinia, Mostafa

AU - Reiter, Russel J

AU - Asemi, Zatollah

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Skin cancer, particularly melanoma, is a leading cause of death worldwide. The therapeutic methods for this malignancy are not effective, and due to the side effects of these treatments, applying an appropriate alternative or complementary treatment is important. According to available data, melatonin as the main product of the pineal gland has oncostatic and antitumoral properties. Also, melatonin acts as an anti-inflammatory and reactive oxygen species inducer agent which suppresses the growth of tumors. It also has apoptosis induction characteristics through regulating signaling pathways, including heat shock protein 70, nuclear factor-erythroid 2 p45-related factor 2 and others. Thus, adding melatonin to chemo- and radiotherapy may have synergistic therapeutic effects and increase the survival time in patients with skin cancer. Few clinical studies have evaluated the efficacy of melatonin in skin cancer. Based on the related mechanisms, this review discusses about how melatonin may improve outcomes in skin cancer patients.

AB - Skin cancer, particularly melanoma, is a leading cause of death worldwide. The therapeutic methods for this malignancy are not effective, and due to the side effects of these treatments, applying an appropriate alternative or complementary treatment is important. According to available data, melatonin as the main product of the pineal gland has oncostatic and antitumoral properties. Also, melatonin acts as an anti-inflammatory and reactive oxygen species inducer agent which suppresses the growth of tumors. It also has apoptosis induction characteristics through regulating signaling pathways, including heat shock protein 70, nuclear factor-erythroid 2 p45-related factor 2 and others. Thus, adding melatonin to chemo- and radiotherapy may have synergistic therapeutic effects and increase the survival time in patients with skin cancer. Few clinical studies have evaluated the efficacy of melatonin in skin cancer. Based on the related mechanisms, this review discusses about how melatonin may improve outcomes in skin cancer patients.

KW - malignancy

KW - melanoma

KW - Melatonin

KW - skin cancer

UR - http://www.scopus.com/inward/record.url?scp=85059607933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059607933&partnerID=8YFLogxK

U2 - 10.1002/jcp.28129

DO - 10.1002/jcp.28129

M3 - Article

JO - Journal of Cellular Physiology

JF - Journal of Cellular Physiology

SN - 0021-9541

ER -